Potential of Oyster Mushroom (Pleurotus ostreatus) secondary metabolites on KRAS protein in-silico liver cancer

Liver Cell Carcinoma (KSH) currently ranks as the fourth most common cause of death due to cancer worldwide and is the sixth most common cancer in the world. HCC (Hepatocellular Carcinoma) is caused by environmental factors, viral infections, and certain genetic changes. Ras is a very important oncogene and is hypermutated in various types of cancer, including HCC. The doxorubicin compound is a curative agent that is widely used for chemotherapy treatment of various types of cancer, however, administration of the kura agent with high cytotoxic activity can cause several side effects. Secondary metabolite compounds have anti-oxidant capabilities including breaking free radical chains and chelating redox-active metal ions which cause lipid peroxidation. These properties also help prevent cancer. Pleurotus otstreatus bioactive compounds that have antioxidant potential, flavonol. Due to the potential cytotoxic activity of these secondary metabolites, a bioinformatics approach is needed in this research to determine the results of predicting the interaction activity of flavonol compounds on the KRAS protein in silico and to determine the amino acids and bonds involved in the interaction. between these compounds and the KRAS protein, as a reference for future HCC drugs. The method used is using the PyRx device, Biovia Discovery Studio, Autodock for the docking process and validating the docking results. The results of this research are that flavonol compounds have a docking value of -7.1 kcal/mol. This compound has the potential as a candidate compound that can be used in liver cancer therapy, because it’s have high values ​​and close to the positive control value, namely doxorubicin, of -7.6 kcal/mol.